Timur I. Davlyatshin

1124, Accounting Quarter 096, Koksay Village, Irgeli Rural District, Karasay District
Almaty, ALA 040921, Kazakhstan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Human and Canine Seropositivity to Toxocara canis in Uralsk, Kazakhstan: Canine Egg Shedding and Evaluation of an Experimental ELISA.

Human and Canine Seropositivity to Toxocara canis in Uralsk, Kazakhstan: Canine Egg Shedding and Evaluation of an Experimental ELISA.

Journal: Pathogens (Basel, Switzerland)

Published: July 20, 2026

Effect of calcitriol on myeloid-derived suppressor cells in physiological aging.

Effect of calcitriol on myeloid-derived suppressor cells in physiological aging.

Journal: The Journal of steroid biochemistry and molecular biology

Published: January 27, 2025

Post-COVID syndrome and type 2 diabetes mellitus in Kazakhstan: clinical manifestations and vaccine efficacy.

Post-COVID syndrome and type 2 diabetes mellitus in Kazakhstan: clinical manifestations and vaccine efficacy.

Journal: Annals of pediatric endocrinology & metabolism

Published: November 07, 2023

Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.

Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up.

Journal: EClinicalMedicine

Published: January 27, 2022

Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.

Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan.

Journal: EClinicalMedicine

Published: April 05, 2021

Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.

Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.

Journal: Human vaccines & immunotherapeutics

Published: February 13, 2020

Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.

Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.

Journal: Human vaccines & immunotherapeutics

Published: November 08, 2017

Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.

Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.

Journal: Journal of medical virology

Published: June 29, 2017

Showing 1-8 of 8

Last Updated: 09/26/2026